The establishment of the US Patent Trial and Appeal Board (PTAB) in 2012 changed the game for patent owners. And while life science patents have not always been under the spotlight, recent trends suggest more such patents are being reviewed than ever before.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
2 October 2026 AI is helping legal and IP teams handle more work without adding headcount, but in-house counsel at LSPN Europe warn that knowing when not to rely on the technology is just as important as knowing how to use it.
1 October 2026 With patent validity increasingly being fought over in both the UPC and EPO, Genevant Sciences’ Stephan Kutik talks to LSIPR about keeping parallel proceedings aligned and why teamwork matters.
1 October 2026 LSPN Europe made its Basel debut, and two days of conversations showed just how much is changing for life sciences professionals—both in how they work and what they are being asked to do. Marisa Woutersen tallies up the talking points.